Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial Fibrillation

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02007655

Enrollment

6372

Registered

2013-12-11

Start date

2013-09-01

Completion date

2016-08-31

Last updated

2022-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NonValvular Atrial Fibrillation

Keywords

Cardiovascular

Brief summary

The primary objectives of this study are: * To estimate the incidence rate of unexpected adverse events * To characterize the bleeding events and assess risk factors of bleeding * To identify ancillary baseline variables that may also be associated with adverse outcomes

Interventions

DRUGEliquis

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Inclusion Criteria: * Patients who are beginning to receive the treatment with this product under the approved indications, dosage, and administration will be included in this study

Exclusion criteria

* Patients who are receiving Eliquis outside of its approved indication will be excluded from this study

Design outcomes

Primary

Measure	Time frame
Incidence rate of unexpected adverse events	Day 1 (At Eliquis initiation)
Bleeding events and risk factors of bleeding	Day 1 (At Eliquis initiation)
Ancillary baseline variables that may also be associated with adverse outcomes	Day 1 (At Eliquis initiation)

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026